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ABSTRACT  
Rubella is a vaccine- preventable viral infection. Its etiologic agent, rubella virus was identified as a human teratogen 
capable of causing spectrum of birth defects described as congenital rubella syndrome (CRS) if the pregnant mother is 
infected within the first trimester of pregnancy. A total of 90 pregnant women attending a secondary health care 
facility in Maiduguri were screened for IgM and IgG antibodies using enzyme linked immunosorbent assay (ELISA) 
kit (Cortez Diagnostics Inc. USA). Of these, 37.8% (34/90) and 83.3% (75/90) were seropositive for anti-rubella IgM (x2 
Cal 5.1; p=0.05) and IgG respectively. Chi-square analysis (x2 Cal 38.38, p=0.05// x2 tab 31.41, p=0.05) revealed an 
association between miscarriage and IgG antibody level in twenty-one subjects. Pregnant women within 20-24years 
had the highest prevalence of 40% (36/90)( x2 Cal 4.22, p=0.05) : 44.4% (16/36) of them were seropositive for IgM (x2 Cal 
4.31, p=0.05). A marked surge in IgG antibody level, which tantamount acute infection, was observed in 15.6% (14/90)( 
x2 Cal 19.85, p=0.05) of the pregnant women. Pregnant women in the first trimester seropositive for anti-rubella IgM 
were 36.4% (4/11), inferring that the fetuses of these women are susceptible to sequelae of rubella. This result 
highlights the consequence of rubella infection and confirms continuous circulation of rubella virus in the study area. 
There is need for vaccination of vulnerable population in order to ensure the control /elimination of rubella virus in 
Nigeria.        
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RESUME 
La rubéole est une infection virale évitable par la vaccination. Son agent étiologique, virus de la rubéole a été identifié 
comme un tératogène humain capable de provoquer le spectre de malformation congénitale décrite comme le 
syndrome de rubéole congénitale (SRC) si la femme enceinte est infectée au cours du premier trimestre de la 
grossesse. Au total, 90 femmes enceintes fréquentant un établissement de soins de santé secondaires à Maiduguri ont 
été dépistées pour le  dosage des anticorps IgM et IgG à l'aide de kit immunoenzymatique (ELISA) (Cortez 
Diagnostics Inc. USA). Parmi elles, 37,8% (34/90) et 83,3% (75/90) étaient séropositives respectivement pour les 
anticorps anti-IgM (X2 Cal. 5,1, p=0,05) et IgG de la rubéole. L’analyse Chi-carré (X2 Cal. 38,38, p=0,05 /X2Tab. 31,41, 
p=0,05) a révélé une relation entre la fausse couche et le niveau d'anticorps IgG dans vingt-et-un sujets. Les femmes 
enceintes de 20 à 24 ans ont eu la plus forte prévalence de 40% (36/90) (X2 Cal. 4,22, p=0,05): 44,4% (16/36) d'entre elles 
étaient séropositives pour les IgM (X2 Cal. 4,31, p=0,05). Une augmentation remarquable de taux d'anticorps IgG, 
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équivalent à l’infection aiguë, a été observée chez 15,6% (14/90) (X2 Cal. 19,85, p=0,05) de femmes enceintes.Les femmes 
enceintes au premier trimestre, séropositives aux IgM anti-rubéole, ont été de 36,4% (4/11), déduisant que les fœtus de 
ces femmes sont sensibles aux séquelles de la rubéole. Ce résultat souligne la conséquence de la rubéole et confirme la 
circulation continue du virus de la rubéole dans la zone d'étude. Il est nécessaire de vacciner la population vulnérable 
afin d'assurer le contrôle et/ou l’élimination du virus de la rubéole au Nigeria. 
Mots clés: virus de la rubéole, tératogènes, anticorps, Maiduguri 
 
INTRODUCTION 
Infection with rubella virus during pregnancy, 
especially during the first trimester, can result in 
congenital rubella syndrome (CRS) (1). The 
burden of rubella infection in most developing 
countries is however not well documented 
because of lim-ited epidemiological data (2).  
 
The symptoms of rubella infection include a rash, 
low-grade fever, arthralgia, and 
lymphadenopathy. In most cases, the disease is 
self-limiting and rarely causes complications (3). 
Complications of CRS may include miscarriage 
and severe abnormalities of the fetus, such as 
cataracts, retinopathy, heart defects, neurological 
deficits, and deafness (4).  
 
No antiviral drugs are available for treating 
rubella or preventing transmission to the fetus. 
Vaccination programs are regarded as an 
effective tool to eliminate rubella and congenital 
rubella (5).  
 
WHO estimates that worldwide more than 
100,000 children are born with CRS each year, 
most of them in developing countries (6). 
 
In some African Countries, 80% of children have 
been found to be positive for rubella antibodies 
by the age of 10 years (7). Post-epidemic rubella 
antibody prevalence in Ghana has been found to 
be 92% among pregnant women, with 
susceptibility associated with a younger age. In 
Eritrea, the prevalence of antibodies to rubella 
has been reported to be as high as 99% in some 
female population (3).  
 
In Nigeria, past studies have revealed 14.3%, 
3.9%, 10%, 16.3%, prevalence of anti-rubella IgM 
in Abuja, Benue, Benin and Ilorin respectively (2, 
8, 9, 10) while 53%, 62.7%, 68.5%, 54.1% 
prevalence of anti-rubella IgG in Benin, Zaria,  
Ibadan, and Maiduguri respectively (9, 11, 12, 13) 
have been reported. 
 
Till date there is no national program to 
vaccinate children and women against rubella 
(14). This indicates that rubella immunization is 
not included in Nigeria immunization schedule 
and thus infections during pregnancy may still 
occur.  
 
The possibility of occurrence of rubella in Nigeria 
is corroborated by report of “a Nigerian woman 
who arrived in the United States in early March 
2012 in approximately week 32 of pregnancy. In 
the United States, her pregnancy was 
complicated with oligohydramnios and severe 
growth retardation. She did not recall having had 
a rash illness during her pregnancy. Maternal 
serum collected 3 days after she had given birth 
tested negative at CDC for rubella IgM and 
positive for rubella IgG with a high avidity index. 
In March 2012, she was delivered of an infant in 
Alabama by cesarean delivery at 33 weeks' 
gestational age. At birth, the infant had 
generalized hemorrhagic purpura (a blueberry 
muffin rash) over the entire body, patent ductus 
arteriosus, cardiomegaly, thrombocytopenia, 
pneumonitis, anemia, and liver dysfunction. 
Approximately 1 month later, the infant was 
transferred to a pediatric hospital, where the 
infant died in April 2012. Cause of death was 
recorded as CRS (1). 
 
No serological evaluation of combined IgG and 
IgM antibodies for previous and current rubella 
infections has been reported in a single study in 
the study area.  
 
Therefore this study was carried out to determine 
the sero-prevalence of maternal anti-rubella IgG 
and IgM in pregnant women attending a 
secondary health facility in Maiduguri, Nigeria 
and to generate baseline data which can serve to 
prompt relevant health authority to appreciate 
the need to formulate feasible, implementable 
policy to mitigate the sequelae of rubella virus 
infection, not only in the study area but the 
country at large. 




This research was carried out in Fatima Ali 
Sheriff health center, Maiduguri, Borno State, 
Nigeria. The research spanned January – 
November 2013. Maiduguri is the capital of 
Borno State located in the north eastern region of 
Nigeria. The indigenes are predominantly Kanuri 
by tribe. 
Ethical Clearance 
Ethical approval for the study was obtained from 
the Ethical Board of the hospital. Informed oral 
consent was obtained from all subjects recruited 
into the study.   
Study design 
To allow for fair representation of sample, a 
cross-sectional, hospital –based design was 
utilized. Out of the one hundred and twenty 
antenatal attendees intended for the study, only 
ninety (75%) whose consent was sought and 
obtained participated in the research. A 
structured questionnaire was administered on 
each pregnant woman to obtain necessary 
demographic data which included age, trimester 
of pregnancy, history of measles, mumps, rubella 
(MMR) vaccination and experience of skin rash.    
Exclusion criteria 
Women who are not pregnant were excluded 
from the research. 
Inclusion criteria 
Only pregnant women were included in the 
research.   
        
Specimen collection 
Three milliliter (3ml) of blood was aseptically 
collected by venipuncture and serum was 
obtained by centrifuging at 3000rpm for 5 
minutes (Agbede et al., 2011). Serum was kept 
frozen at -200C in the Department of 
Immunology, University of Maiduguri Teaching 
Hospital until analysis was done. 
Specimen Analysis   
The Enzyme linked immunosorbent assay 
technique was employed for both IgM and IgG 
antibodies. Abiding strictly by  manufacturer’s 
instruction (Diagnostic Automation, Inc. U.S.A), 
one in forty (1:40) dilutions of specimen, negative 
control, positive control and calibrator were 
prepared by adding 5µl  of the aforementioned to 
200µl of sample diluent and mixed well. One 
hundred microliter (100µl) of diluted sera, 
calibrator and controls were dispensed into the 
appropriate wells. One hundred microliter 
(100µl) of absorbent solution was dispensed in 
1A well position for the reagent blank. The 
holder was tapped to remove air bubbles from 
the liquid and was mixed well and incubated for 
30 minutes at room temperature. Liquids from all 
wells were removed and washed three times 
repeatedly with washing buffer. One hundred 
microliter (100µl) of enzyme conjugate was 
dispensed into each well and incubated for 30 
minutes at room temperature. The enzyme 
conjugate was then removed from all wells and 
washed repeatedly three times with washing 
buffer. One hundred microliter (100µl) of TMB 
Chromogenic Substrate was dispensed to each 
well and incubated for 15 minutes at room 
temperature. Then 100µl of 2 N HCl was added 
to stop reaction. While ensuring there were no air 
bubbles in each well, O.D. at 450 nm was read 
with a microwell reader. 
Interpretation of Result 
Based on manufacturer’s instruction (Diagnostic 
Automation, Inc. U.S.A), the mean value of 
Rubella G Index for each specimen was 
calculated by dividing the mean absorbance 
value of each sample by the cut off calibrator 
mean value. A sample was then considered 
positive for anti-Rubella IgG and IgM antibody 
whenever a Rubella G and M Index value is 
equal to or greater than 1.0, and considered 
negative whenever a Rubella G and M Index 
value is equal to or less than 0.90. 
 
Criteria for the validity of the IgM assay  
 
The assay was considered valid: 
1. When the OD450nm of the A1 blank 
well was <0.150 
2. When the OD450 nm of the calibrator 
was >0.250 
Criteria for the validity of the IgG assay  
 
The assay was considered valid: 
1. When the OD450nm of the A1 blank 
well was <0.250 






An overall prevalence of 37.8% and 83.3% for 
anti-rubella IgM and IgG antibodies respectively 
were obtained in this study (Table 1). Pregnant 
women within the age bracket 15-19years and 20-
24years combined, constitute 58.88% of the 
respondents (Table 1) while majority, 62.22% to 
be precise, of the pregnant women sampled were 
in the third trimester of pregnancy. None of the 
respondent (0%) was 40years old (Table 1). 
Prevalence of pregnant women in the first 
trimester seropositive for rubella IgM was 36.4% 
(Table 1). There was evidence of marked surge in 
IgG antibody level among fourteen (15.6%) 
pregnant women (Table 2). Chi-square analysis 
(x2 Cal 38.38, p=0.05// x2 tab 31.41, p=0.05) 
revealed an association between miscarriage and 
IgG antibody level in twenty-one pregnant 
women (Table 1).   
 
TABLE 1: DISTRIBUTION OF ANTI-RUBELLA ANTIBODIES AMONG PREGNANT WOMEN 
Variable   n  IgM(+ve)  IgG(+ve) 
Age 
15-19   17     06       14 
20-24*   36     16       30 
25-29   15     04       14 
30-34   16     07       14 
35-39   06     01       03 
≥40   00     00       00 
Trimester 
First    11    04      10 
Second   23    10      20 
Third   56    25      45 
History of Miscarriage 
Yes   27   13      21** 
No   63   27      56 
History of MMR 
Vaccination 
Yes   0  0      0 
No    90  34      75 
Experience of 
Rashes 
Recent   90  34     20 
Past    90  56     75 




TABLE 2: MARKED SURGE IN ANTI-RUBELLA IGG ANTIBODY AMONG PREGNANT WOMEN 
            Sample No           Rubella G Index of   Rubella G Index of                                Ratio of 
              Convalescent(RGIC)                 Pre-vaccination(RGIP)                                     RGIC/RGIP 
17  3.150     0.9    3.5 
23  3.527     0.9    3.9 
24  4.435     0.9    4.9 
31  5.532     0.9    6.1 
54  3.561     0.9    3.9 
79  3.536     0.9    3.9 
80  3.381     0.9    3.7 
81  3.092     0.9    3.4 
86  3.054     0.9    3.3 
87  3.728     0.9    4.1 
89  3.158     0.9    3.5 
96  3.117     0.9    3.4 
99  3.364     0.9    3.7 
144  3.096     0.9     3.4 
Manufacturer: RGIC/RGIP should be >1.5 to be suggestive of significant rise in    antibody level. 
 
DISCUSSION 
This is the first serological evaluation of combined 
IgM and IgG antibodies among pregnant women in 
Maiduguri, Nigeria. The result of this study reveals 
37.8% and 83.3% IgM and IgG seroprevalence 
respectively. The 37.8% IgM prevalence in this study 
is high compared to the 14.3%, 3.9%, 10%, and 16.3% 
prevalence in Abuja, Benue, Benin and Ilorin 
respectively (2, 8, 9) while the 83.3% IgG prevalence 
obtained in this study is also comparatively higher 
than the 53%, 62.7%, 68.5% prevalence in Benin, Zaria 
and Ibadan (9, 11, 12, 13,). Bukbuk et al., (2002) had 
earlier reported a 54.1% IgG seroprevalence in 
Maiduguri, but eleven years on, the prevalence of 
83.3% in this study implies that more women have 
been and are perhaps still being exposed to rubella 
virus.  
 
The age-stratified prevalence of anti-rubella 
antibodies among the pregnant women within the 20-
24years revealed the highest prevalence of 40% 
(36/90)( x2 Cal 4.22, p=0.05). We observed also that a 
combination of the 15-19years and 20-24years age 
bracket constituted a 58.88% of the pregnant women 
sampled in this study. This is instructive in that it 
shows that majority of the women in the area of study 
enter into childbearing early i.e. between 15-24years 
of age. This is in consonance with the tradition of 
early marriage in the northern part of Nigeria. None 
of the pregnant women sampled in this study was up 
to forty years of age. This is not unexpected since at 
such age, in northern Nigeria, many a woman would 
have become a grandmother due to early marriage. 
 
The predominance of first time visitors (62.22%) to 
antenatal clinics at the third trimester of pregnancy 
was observed in this study (Table 1). This implies that 
majority of pregnant women either do not attend at 
all or present late at the antenatal clinics for routine 
medical attention. This attitude would impact 
negatively on any possible future effort to conduct 
surveillance on the prevalence of, and mitigate 
occurrence of children born with congenital rubella 
155 
  
syndrome in the study area in particular and Nigeria 
in general. This highlights the utmost importance of 
educating women of childbearing age in the study 
area on the need to enroll immediately in antenatal 
clinics whenever they are pregnant. 
 
Rubella virus infection usually causes a mild disease 
in humans, but infection during early pregnancy 
often leads to severe congenital abnormalities (15). 
Therefore, the fetuses of 36.4% (4/11) of the pregnant 
women in the first trimester who were seropositive 
for IgM are at risk of severe congenital abnormalities. 
It also implies that had the pregnant women in the 
second trimester (76.9%; 10/13) and those in the third 
trimester (80.6%; 25/31) seropositive for IgM 
contracted this virus earlier, their fetuses would have 
also been at great risk of malformation (Table 1). 
 
In this study, 10% (9/90) of the pregnant women were 
IgM and IgG anti-rubella antibodies negative. This 
means that they constitute population at risk. They 
are susceptible to infection by rubella virus. Among 
these nine, three (33.3%; 3/9) had history of 
pregnancy loss. This is indicative of miscarriage of 
non-rubella aetiology. The loss could only be 
attributed to other teratogenic organisms. However, 
23.33% (21/90) of the pregnant women seropositive 
for rubella IgG had history of miscarriage while Chi-
square analysis (x2 Cal 38.38, p=0.05// x2 tab 31.41, 
p=0.05) revealed an association between miscarriage 
and IgG antibody level in these category of pregnant 
women. This further corroborates the assertion by 
previous researchers that miscarriage is a sequelae of 
rubella virus infection.  
Six point seven percent (6.7%; 6/90) of the pregnant 
women were IgM seropositive and IgG negative  
inferring that these pegnant women are undergoing 
acute infection. None of them was found to be in the 
first trimester of pregnancy, although two (2/6) of 
them had history of pregnancy loss. Even though they 
were IgM positive, rubella virus could not have been 
responsible for the past pregnancy loss due to the IgG 
seronegative status. 
 
A marked surge in anti-rubella IgG antibody level 
was observed in fourteen of ninety pregnant women 
sampled (15.55%; x2 Cal 19.85, p=0.05 // x2 tab 22.36, 
p=0.05). This marked rise in antibody level is the ratio 
between the Rubella G Index of convalescent sample 
and that of pre-vaccination sample, which should be 
greater than 1.5 (Diagnostic Automation, Inc, USA). 
Manufacturer’s manual specified Rubella G Index of 
0.9 or less to be seronegative for IgG antibody to 
Rubella virus. None of the pregnant women in this 
study had any history of Rubella vaccination, 
therefore we assume pre-vaccination value to be 0.9 
while the Rubella G Index of convalescent sample 
(after natural exposure, as the case in this study) is 
value obtained after analysis of sera (Table 3). The 
high ratio obtained for this samples (Table 3) is 
suggestive of recent infection even in the absence of 
IgM antibodies especially had further analysis 
revealed IgG with  high avidity index. Due to scarce 
resources, however, avidity indices for these IgG 
antibodies were not determined.  
 
In conclusion, the result of this work has revealed that 
rubella virus is still in circulation in the study area 
and that more women have been and are perhaps still 
being exposed to this potentially hazardous 
teratogenic agent responsible for several unreported 
cases of its sequelae- congenital rubella syndrome.  
 
We recommend, therefore, that relevant authority 
devise drastic measure to be taken to protect women 
of childbearing age and fetuses from this scourge by, 
beside other measures, including rubella vaccination 
in routine antenatal screening exercise in Nigeria. 
There is also the need to health-educate women of 
childbearing age on how they could protect 
themselves from contracting this virus.  
 
Acknowledgement 
We are grateful to all the member of staff of Fatima 
Ali Sheriff Hospital, Maiduguri for helping in the 
course of sample collection. We also thank Mal. Ali of 
the Department of Immunology, University of 
Maiduguri Teaching Hospital for the help he 




1. Morbidity and Mortality Weekly Report: 
Three Cases of Congenital Rubella 
Syndrome in the Post elimination Era — 
Maryland, Alabama, and Illinois, 2012.  
March 29, 2013 / 62(12); 226-229 
 
2. Enya, B.,  Effiong, M. A., Moffat, U. S. and 
Emem, B. (2011). Incidence of rubella IgM 
antibodies in individuals with febrile rash 
illness attending clinics in Akwa Ibom State, 




3. Junaid, S. A., Akpan, K. J. and O
O. (2011). Sero-survey of rubella IgM 
antibodies among children in Jos, Nigeria. 
Virology Journal 8:244 
 
4. Ching-Chiang, L., Chun-Yuh, Y., Ching
Tang, S., Bai-Hsiun, C., Yeou-Lih, H. (2010). 
Rubella Seroepidemiology and Catch
Immunization among Pregnant Women in 
Taiwan: Comparison between Women Born 
in Taiwan and Immigrants from Six 
Countries in Asia. Am J Trop Med Hyg
82(1):40-44.  
 
5. Dontigny, L., Arsenault, M.Y., Martel, M.J., 
Biringer, A., Cormier, J., Delaney, M., 
Gleason, T., Leduc, D., Martel, M.J., Penava, 
D., Polsky, J., Roggensack, A., Rowntree, C. 
and Wilson, A.K. (2008). 
pregnancy. J Obstet Gynaecol Can
 
6. Shaheen, R., Kakru, D.K., Kauser, R., Gaash, 
B. and Hussain, S.N. (2008) Seroprevalence 
of rubella antibod-ies in Kashmiri pregnant 
women. Indian J. of the Practising. Doc.
 
7. Gomwalk, N.E. and Ahmed, A.A (1989). 
Prevalence of rubella antibodies in
African continent. Rev. of infect. Dis.
21. 
8. Pennap, G., Amauche, G., Ajoge, H., Gabadi, 
S., Agwale, S. and Forbi, J. (2009). Serologic 
Survey of Specific Rubella Virus IgM in the 
Sera of Pregnant Women in Makurdi, Benue 









, 30152-158.  




9. Onakewhor, J. U., and Chiwuzie, J. (2011). 
Seroprevalence survey of rubella infection in 
pregnancy at the University of Benin 
Teaching Hospital, Benin City, Nigeria. 
J Clin Pract;14:140-5  
10. Agbede, O.O., Adeyemi, O.O., Olatinwo, 
A.W.O., Salisu, T.J. and Kolawole, O.M. 
(2011). Sero-Prevalence of Antenatal Rubella 
in UITH. The Open Public Health Journal 
10-16 
11. Oyinloye, S.O., Ahmad, A. A, Jatau, E.D. 
(2009). Seroprvalence of rubella virus 
infection in Zaria, Nigeria: An association 
between antibody level and community 
setting,  Biological and Environmental Sciences 
Journal for the Tropics 9, 56
 
12. Bamgboye, A.E., Afolabi, K.A., Esumeh, F.I., 
Enweani. I.B.( 2004). Prevalence of rubella 
antibody in pregnant women in Ibadan, 
Nigeria. West Afr J Med; 23: 245
 
13. Bukbuk, D.N., EL-Nafaty, A.U., Obed, J.Y.( 
2002). Prevalence of rubella specific IgG 
antibody in non-immunized pregnant 
women in Maiduguri, North Eastern 
Nigeria. Cent. Eur J Public Healt
3. 
 
14. Adeyemi, O.O., Agbede, O.O., Kolawole, 
M.O. and Okoh, A. (2012). Knowledge, 
attitude, and practices of pregnant women 
attending university of Ilorin Teaching 
Hospital with regard to rubella. Journal of 
Family and Reproductive Health (6)4:
158  
 
15. Jila, S., Hasan, E. and Kazem, M. (2005) 
Congenital rubella syndrome in Iran. 
Infectious Diseases, 5, 44. 
2334-5-44  
 
157 
Niger 
 4, 
-58 
-8. 
h 10(1-2): 21-
 153-
BMC 
doi:10.1186/1471-
